Compare · BDMD vs BSX
BDMD vs BSX
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.77B, about 1527.7x BDMD ($43.1M).
- Over the past year, BDMD is down 47.8% and BSX is down 58.2% - BDMD leads by 10.3 points.
- BSX has more recent analyst coverage (25 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- Boston Scientific Corporation
- Price
- $1.08+1.89%
- $44.27+1.54%
- Market cap
- $43.1M
- $65.77B
- 1M return
- +7.46%
- -0.43%
- 1Y return
- -47.83%
- -58.17%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BDMD
- Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina
- Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion
- SEC Form POS AM filed by Baird Medical Investment Holdings Ltd
- SEC Form F-3 filed by Baird Medical Investment Holdings Ltd
- SEC Form SCHEDULE 13G filed by Baird Medical Investment Holdings Ltd
- Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
- SEC Form 20-F filed by Baird Medical Investment Holdings Ltd
- SEC Form 3 filed by new insider Xu Lijian
- SEC Form 3 filed by new insider Qiu Quan
- SEC Form 3 filed by new insider Lu Rongjian
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints